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Bacterial meningitis is a major global cause of morbidity and mortality. Rapid identification of the aetiological
agent of meningitis is essential for clinical and public health management and disease prevention given the
wide range of pathogens that cause the clinical syndrome and the availability of vaccines that protect against
some, but not all, of these. Since microbiological culture is complex, slow, and often impacted by prior anti-
microbial treatment of the patient, molecular diagnostic assays have been developed for bacterial detection.
Distinguishing between meningitis caused by Neisseria meningitidis (meningococcus), Streptococcus pneumo-
niae (pneumococcus), Haemophilus influenzae, and Streptococcus agalactiae and identifying their polysaccha-
ride capsules is especially important. Here, we review methods used in the identification of these bacteria,
providing an up-to-date account of available assays, allowing clinicians and diagnostic laboratories to make
informed decisions about which assays to use.
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Bacterial meningitis, which can be accompanied by sepsis, is an
infection causing significant morbidity and mortality worldwide [1].
Many pathogens can invade the membranes lining the brain and spi-
nal cord and cause syndromic meningitis; however, the condition
can become rapidly fatal if untreated when caused by the encapsu-
lated bacteria Haemophilus influenzae, Neisseria meningitidis (menin-
gococcus), Streptococcus pneumoniae (pneumococcus), and
Streptococcus agalactiae (group B streptococci, GBS). In adults, olderchildren, and adolescents (aged 1019 years) bacterial meningitis
caused by these organisms typically presents with symptoms includ-
ing headache, fever, photophobia, vomiting, and neck stiffness [2]. In
newborns (1 to 28 days), infants (up to 12 months) and young chil-
dren (from 1 to 10 years), the symptoms and signs are non-specific,
including lethargy, poor feeding, vomiting and irritability associated
with fever [3]. Rapid, accurate and specific identification of the causa-
tive organism is necessary to ensure an effective public health
response is elicited and appropriate clinical management, such as
antimicrobial prophylaxis, can be established with or without vacci-
nation of contacts.
The development and implementation of conjugate polysaccha-
ride vaccines at the turn of the century transformed public health
Table 1
Current status of vaccines against H. influenzae, N. meningitidis, S. pneumoniae and S. agalactiae.
Bacterial species Licensed vaccines and targets Vaccines in clinical development References
Haemophilus
influenzae
ActHIB, Sanofi Pasteur Hib (PRP-T)
Hiberix, GSK Vaccines Hib (PRP-T)
PedvaxHIB, Merck Hib (PRP-OMP)
Combination vaccines:
Pentacel/Pentaxim, Sanofi Pasteur (DTaP, IPV, Hib [PRP-T])
Hexaxim/Hexyon, Sanofi Pasteur (DTaP, IPV, Hib [PRP-T], HBV)
Vaxelis, Sanofi (DTaP, IPV, Hib [PRP-OMP], HBV)
Infanrix Penta, GSK Vaccines (DTaP, IPV, Hib [PRP-T])
Infanrix Hexa, GSK Vaccines (DTaP, IPV, Hib [PRP-T], HBV)
Menitorix, GSK Vaccines (Hib [PRP-T], MenC [PsC-T])





Menomune, Sanofi Pasteur (PsA, PsC, PsW, PsY)
Mencevax/ACWYVax, Pfizer (PsA, PsC, PsW, PsY)




Menactra, Sanofi Pasteur (PsA-D, PsC-D, PsW-D, PsY-D)
Menveo, GSK Vaccines (PsA-CRM197, PsC-CRM197, PsW-CRM197,
PsT-CRM197)
Mejugate, GSK Vaccines (PsC-CRM197)
Nimenrix, Pfizer (PsA-T, PsC-T, PsW-T, PsY-T)
NeisVac-C, Pfizer (PsC-T)
MenAfriVac, Serum Institute of India (PsA-T)
Menitorix, GSK Vaccines (Hib [PRP-T], MenC [PsC-T])
Menhibrix, GSK Vaccines (Hib [PRP-T], MenCY [PsC-T, PsY-T])
MenQuadfi, Sanofi Pasteur (MenACWY, [PRP-T])
Polysaccharide-protein conjugate vaccines:
NmCV-5, Serum Institute of India
(PsA-T, PsCCRM197, PsW-CRM197,
PsX-T, PsY-CRM197)
Outer membrane vesicle vaccines:
VA-MENGOC-BC, Finlay Institute Vaccine, Cuba (CU385/83 B:4:
P1.19, 15) (no longer in production)
Protein-based vaccines:
Bexsero (4CMenB), GSK Vaccines (NZ98/254 OMV, FHbp, NadA,
NHPA)





1, 2, 3, 4, 5, 6B, 7F, 8, 9 V, 9 N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F,
19A, 20, 22F, 23F, 33F
[86]
Polysaccharide-protein conjugate vaccines:
SynflorixTM, GSK Vaccines (10-valent)  serotypes:
1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19F, 23F
Prevenar/Prevnar , Pfizer (13-valent)  serotypes:
1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 23F
Pneumosil, Serum Institute of India (10-valent)  serotypes:
1, 5, 6A, 6B, 7F, 9 V, 14, 19A, 19F, 23F
Polysaccharide-protein conjugate vaccines in Phase
3 clinical trials:
V114, MSD (15-valent)  serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V,
14, 18C, 19A, 19F, 22F, 23F, and 33F
20vPnC, Pfizer (20-valent)  serotypes: 1, 3, 4, 5, 6A, 6B, 7F,
8, 9 V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F
Streptococcus
agalactiae
Licenced vaccines not yet available Pfizer: Up to 6-valent vaccine recruiting for trials
Minervax:




Known capsular polysaccharides among the four major bacterial meningeal
pathogens.
Bacterial species Known capsular types
Haemophilus influenzae a b, c, d, e, f
Neisseria meningitidis A, B, C, E, H, I, K, L, W, X, Y and Z
Streptococcus pneumoniae 1, 2, 3, 4, 5, 6A, 6B, 6Bii (6E), 6C, 6D, 6F, 6 G, 6H,
7F, 7A, 7B, 7C, 8, 9A, 9 L, 9 N, 9 V, 10F, 10A, 10B,
10C, 11F, 11A, 11B, 11C, 11D, 11E, 12F, 12A,
12B, 13, 14, 15F, 15A, 15B/C, 16F, 16A, 17F, 17A,
18F, 18A, 18B, 18C, 19F, 19A, 19B, 19C, 20A,
20B, 21, 22F, 22A, 23F, 23A, 23B, 24F, 24A, 24B,
25F, 25A, 27, 28F, 28A, 29, 31, 32F, 32A, 33F,
33A, 33B, 33C, 33D, 33E, 34, 35F, 35A, 35B, 35C,
36, 37, 38, 39, 40, 41F, 41A, 42, 43, 44, 45, 46,
47F, 47A, 48
Streptococcus agalactiae Ia, Ib, II, III, IV, V, VI, VII, VIII, IX
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viding vaccines that elicited individual protection and herd immunity
against three of the most common causes of meningitis: the menin-
gococcus; the pneumococcus; and H. influenzae (Table 1) [4]. Each
polysaccharide vaccine, however, generates a highly specific immune
response only to the polysaccharide antigens it contains. In the case
of H. influenzae, one capsular type known as serotype b (Hib) is more
commonly associated with causing disease, and monovalent vaccines
against Hib have been highly successful. However, other serotypes
(such as serotype a) are increasing in North America and broader vac-
cine development may be required [5]. For the meningococcus, six of
the twelve capsular groups (known as serogroups A, B, C, W, X, and Y)
cause the majority of meningococcal invasive disease. Conjugate vac-
cines are available for A, C, W, and Y: a serogroup X conjugate vaccine
is in clinical trials, and alternative protein-based vaccines are avail-
able which protect against a number of meningococci including some
that express serogroup B capsules [6].
For the pneumococcus the challenge is greater, since there are a
large number of capsular serotypes associated with invasive pneu-
mococcal disease and current vaccines only cover up to 13 of these
(Table 2). Furthermore, although there are vaccines underdevelopment, no licenced vaccine against GBS was available at the
time of writing [7]. Notwithstanding these limitations, the wide-
spread implementation of available conjugate vaccines has resulted
in a range of public health benefits including: (i) The global decrease
Fig. 1. Approaches used in the diagnosis of meningitis from cerebrospinal fluid.
Figure created with BioRender.com.
K. Diallo et al. / EBioMedicine 65 (2021) 103274 3of invasive disease due to Hib [8]; (ii) The decrease in serogroup C
meningococcal disease in countries that implemented the serogroup
C conjugate vaccine; (iii) The near disappearance of serogroup A
meningococcal infections in the African meningitis belt; and (iv)
Major reductions in invasive pneumococcal disease globally
[4,911].
Given the diversity of organisms that can cause meningitis, accu-
rate species and capsule identification is essential for diagnosis, treat-
ment, surveillance, and public health intervention. This ensures thatrelevant measures are implemented for case and outbreak manage-
ment and also informs future vaccine development. A global initiative
aimed at eliminating meningitis worldwide by 2030 has recently
been endorsed by the WHO (https://www.who.int/activities/defeat
ing-meningitis-by-2030). One of five pillars of the roadmap for this
global vision is “Diagnosis and treatment” and it highlights the need
for comprehensive, cost-effective diagnostic approaches to enhance
surveillance [12]. A number of diagnostic assays have been developed
(Fig. 1). Here, we provide an account of recently published molecular
4 K. Diallo et al. / EBioMedicine 65 (2021) 103274diagnostic assays and report on the developments made in this field.
Clinicians and diagnostic laboratories can use this information to
make decisions on assay suitability and identify areas that require
further research.
1.1. Point-of-care assays
Characterisation of organisms by culture from a normally sterile
site, such as cerebrospinal fluid (CSF), has long been the mainstay of
the laboratory confirmation of suspected bacterial meningitis [2].
However, several factors impede the use of CSF culture for diagnosis,
including: the fact that it can take 2448 h or longer to obtain culture
results [13]; suboptimal CSF specimen volume; fastidious, difficult to
cultivate organisms; suboptimal storage and transportation; and
prior antimicrobial administration resulting in non-viable bacteria.
Consequently, a variety of approaches have been developed for the
diagnosis of bacterial meningitis, including: latex agglutination, lat-
eral flow assays, and molecular diagnostic assays (Fig. 1).
Although sero-agglutination assays are among the simplest tests
to execute, their sensitivity can be reduced if the patient received
antimicrobial treatment prior to specimen collection [14]. Agglutina-
tion assays also depend on expression of the target antigen, most
often the polysaccharide capsule which bacteria can modulate both
in vitro and in vivo [15,16]. Cross-reactivity due to poly-agglutination
can be problematic for some sero-agglutination assays and can pre-
vent definitive characterisation of the isolate [17]. Lateral flow assays
(LFAs; one example is the commercial pregnancy test), consist of pre-
fabricated strips containing dry reagents that are activated by appli-
cation of a fluid sample [1820]. Several types of LFAs exist and the
greatest benefits of these tests are that they are rapid, single use, and
point-of-care. The different types of LFAs include those in which anti-
bodies are used as recognition elements (‘lateral flow immunoas-
says’). An example of this is the MeningoSpeed rapid diagnostic test,
an immunochromatographic test that can detect meningococcal
serogroups from CSF samples [21]. Other LFAs consist of antigen-anti-
body interactions with specific tagged doubled-stranded amplicon
detection after PCR (‘nucleic acid lateral flow immunoassay’) or
assays where specific nucleic acid amplicons are hybridised with
immobilised complementary probes (‘nucleic acid lateral flow assay’)
[20]. Although the sensitivity of sero-agglutination and LFAs is sus-
ceptible to bacterial viability, the ease and rapidity with which these
assays can be used make these assays desirable in more challenging
low- and middle-income countries (LMIC).
1.2. Endpoint PCR and real-time PCR assays for the detection of
meningitis pathogens
Molecular tools including the polymerase chain reaction (PCR),
real-time PCR (rtPCR), qualitative or quantitative PCR (qPCR), and
loop-mediated isothermal amplification assays (LAMP) have the
potential to overcome many of the limitations of culture-based
approaches, as they target bacterial DNA and are not constrained by
the presence of cultivable organisms. These molecular tools are now
the methods of choice for many laboratories and have improved pub-
lic health measures because they involve standard, generic laboratory
techniques that allow multiple pathogens to be rapidly detected.
Indeed, the World Health Organisation (WHO) recommends the use
of rtPCR in the testing of pneumococcus, meningococcus, and Hib
from suspected cases of meningitis [13]. Major challenges remain,
however, in the deployment of these assays in LMICs, due to the vari-
ability of laboratory capabilities, shortage of trained laboratory per-
sonnel and challenges in procurement of reagents and equipment.
Progress has been made through initiatives such as MenAfriNet
(www.menafrinet.org) and laboratories in several countries in the
African meningitis belt and beyond have acquired the capability to
perform these assays [22].The first molecular methods to be developed were PCR assays that
detect a single pathogen, but these have been largely superseded by
multiplex PCR assays (simultaneous testing of multiple targets) such
as rtPCR assays, which reduces time and consumable costs [23]. Note
that the tests described below are not commercially available except
where indicated.
1.2.1. Haemophilus influenzae
Several singleplex PCR assays detecting Hib have been described,
including those that detect: the capsule gene bexA [24]; the outer
membrane proteins OmpP2 (ompP2) and OmpP6 (ompP6) [25,26];
the phase variable gene licA encoding phosphorylcholine kinase [25];
the protein D gene (hpd) [26,27]; and fuculokinase (fucK) [25]
(Table 3). Although assays targeting fucK and hpd have been shown
to reliably detect Hib [25,28], some non-typeable H. influenzae (NTHi)
strains have been reported to lack either fucK [29] or hpd genes [30]
while some Haemophilus parainfluenzae strains were reported to pos-
sess hpd [28] (Table 3). The ompP2 and ompP6 sequences also display
some diversity, making them difficult targets to detect reliably, and
there is some evidence for cross-reactivity with Haemophilus haemo-
lyticus [31]. The increasing availability of whole genome sequence
data (WGS) will provide further opportunities to determine the prev-
alence, diversity and distribution of these genes within the genus
Haemophilus.
1.2.2. Neisseria meningitidis
Recommended genetic targets for the identification of meningo-
cocci include the superoxide dismutase gene sodC and the capsule
gene ctrA (Table 3) [32,33]. Although sodC is ubiquitous in meningo-
cocci, it has been reported to lead to false positive results due to the
presence of sodC homologues in other bacterial species including H.
influenzae [33], while the ctrA gene preferentially detects encapsulated
meningococci (Table 3). As a result, other tests have been developed,
using the outer membrane protein gene porA and the capsule null
locus (cnl), the combination of which identifies unencapsulated
meningococci, which cause invasive disease rarely, but which are com-
monly found in asymptomatic carriage [33,34]. In such situations, the
host may have a predisposing immunosuppressive condition [35];
however, this also suggests that rtPCR assays that only test for encap-
sulated meningococci may be overlooking cnl strains, and that a com-
bined cnl and ctrA assay may be needed to increase sensitivity.
1.2.3. Streptococcus pneumoniae
The genetic targets used to detect S. pneumoniae include the auto-
lysin gene lytA and the permease gene of the Pia ABC transporter,
piaB, although the latter was reported to be absent in some nontype-
able or serotype 6B pneumococci [36]. Consequently, lytA was the
recommended genetic target for pneumococci at the time of writing
[36]. It has been reported that lytA homologues can be present in
closely-related species of Streptococcus [37], therefore an assay tar-
geting a putative transcriptional regulator of the GntR-family (gene
SP2020), belonging to the core genome of the pneumococcus, was
developed [36] (Table 3). Finally, the pneumolysin gene, ply, as well
as the pneumococcal surface adhesion gene, psaA, have been
described as targets for the detection of pneumococci in rtPCR assays;
however, strains of Streptococcus pseudopneumoniae and viridans
group streptococci can also be positive for these genes, precluding
their use as reliable genetic targets [38].
1.2.4. Streptococcus agalactiae
Singleplex assays detecting GBS have also been developed,
although many of these are optimised for identifying the bacterium
from gut or vaginal colonisation and/or shortly after labour rather than
for the diagnosis of acute infection [39,40]. Four commercial assays are
available: (i) The Becton Dickinson MAX GBS assay; (ii) The ARIES GBS
assay from Luminex Corporation; (iii) The Illumigene Group B
Table 3
Genetic targets used in the detection of the four main causes of bacterial meningitis.
Bacterial species Genetic target and type of
assay
Function Disadvantage (if known) Sensitivity (%) Specificity (%) References
Haemophilus influenzae (Hib) rtPCR
bexA ATP-binding protein (cap-
sule region I)
Does not detect NTHi strains 100 90100 [21]
omP2 Outer membrane protein P2 Less sensitive than fucK or
licA, and requires very
high genome copies for
detection
97.1 100 [25]
omP6 Outer membrane protein P6 Nucleotide sequence
diversity
NA NA [31]
licA Protein LicA Fails to detect some serotype
e isolates
97.1 99.1 [25]
hpd Protein D May be absent in some NTHi
strains
95/95.7 91/ 92.3 [30]
fucK Fuculokinase Deletion of the fucose
operon in some strains




Hib capsule 247 bp region of the capsule 100 100 [62]











sodC Superoxide dismutase Less sensitive in sterile body
fluids, for use in conjunc-




99.6/ 94.7 100/ 77.9 [32]
crgA Transcriptional regulator of
LysR family
Can be found in N.
gonorrhoeae
93 96 [87]
porA Outer membrane porin, PorA Can be found in N. gonor-




ctrA Capsule transport 89/100 100/98.9 [64,65]






lytA Autolysin Possible homologues in
other closely-related spe-
cies leading to false
positives
100 99.5/100 [36,38]
piaB Pia ABC transporter piaB is absent in some pneu-
mococci including some
serotype 6B strains and
absent in some non-type-
able strains
95.3 99.5 [36]
GntR-family SP2020 Putative transcriptional reg-
ulator gene






ply Pneumolysin Can lead to false-positive





lytA Autolysin 100 100 [66]




cfb S. agalactiae CAMP factor some CAMP-negative GBS
may not carry the cfb gene
NA NA [41]




cfb S. agalactiae CAMP factor NA NA [41]
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LB assay produced by Cepheid Inc. Three of these use rtPCR assays,
while Illumigene uses a loop-mediated isothermal amplification
(LAMP) assay with the cfb gene as the primary target. The gene cfb enc-
odes the extracellular pore-forming toxin also known as the CAMP fac-
tor [40]. The Christie-Atkinson-Munch-Peterson (CAMP) test has been
the conventional culture-based test for identifying GBS and differenti-
ates haemolytic versus non-haemolytic GBS. Notably, some GBS iso-
lates are CAMP negative and lack cfb, indicating that further studies
assessing the distribution of cfb are required [41,42]. Another assay
employed a recombinase polymerase amplification (RPA) method to
detect the cfb gene in vaginal swabs and this assay was sensitive and
specific for GBS [43]. All these assays required samples to be enriched
in Lim Broth for 1824 h prior to testing and results demonstrated
greater sensitivity compared with culture alone.
1.3. Multiplex assays
An advantage of using PCR assays in infectious disease diagnostics
is that multiple pathogens may be targeted in a single assay, which
conserves clinical specimens, saves time, and reduces costs. Multiplex
rtPCR assays that detect Hib, meningococci and pneumococci in one
reaction have been developed and can be used to test CSF directly and
avoid the need for DNA extraction [44,45]. One prototype assay has
been developed to detect six microorganisms associated with menin-
gitis including (molecular target): S. pneumoniae (lytA); N. meningitidis
(ctrA); H. influenzae (ompP2); S. agalactiae (cfb); Listeria monocytogenes
(iap); and Cryptococcus neoformans (18S rDNA) [46]. To date, the assay
has been tested using a limited number of specimens and therefore
requires further validation; however, of the 45 suspected cases of bac-
terial meningitis, the causative agent was identified in 32 CSF speci-
mens using a combination of phenotypic and genotypic tests and of
these 16 were identified solely on the basis of molecular assays [46].
More recently, a commercial TaqMan Array card has been devel-
oped that can detect multiple meningitis-associated pathogens [47].
This assay was tested in CSF samples originating from West Africa
and results indicated that diverse infectious aetiological agents were
present. Another commercially available test is the BioFire
FilmArray Meningitis/Encephalitis (ME) Panel which can detect 14
pathogens (seven viruses, six bacteria and one fungus) simulta-
neously from CSF samples, including the four bacteria that are the
focus of this review [48]. Performance of the ME Panel was evaluated
using clinical CSF samples that had previously tested positive using
routine methods: the ME Panel resulted in an overall positive agree-
ment of 97.5% for bacterial pathogens [48]. A study in Ethiopia involv-
ing 218 patients with suspected meningitis identified S. pneumoniae,
N. meningitidis and H. influenzae using the ME Panel, but only in 5
(2.2%) cases [49]. Although the ME Panel has been shown to increase
pathogen detection rate, it has been noted that interpretation and
correlation of results requires experienced users and it does not allow
the capsular polysaccharide to be determined [50]. Furthermore, the
ME Panel may be cost-prohibitive for LMICs since the estimated aver-
age cost is currently around $239 per test (around £180/€200) [51].
It should also be noted that there are several other aetiological
agents of meningitis, some of which are highly prevalent in LMIC set-
tings, including Cryptococcus neoformans; Mycobacterium tuberculo-
sis; Salmonella enterica var Typhi; Herpes simplex virus; Varicella
zoster virus and enteroviruses. C. neoformans and M. tuberculosis in
particular are common among HIV-infected individuals. Inexpensive,
easy to use multiplex assays with the capacity to detect all of these
pathogens need to be developed.
1.4. PCR and rtPCR assays for the detection of capsular types
Once the bacterial species has been confirmed, further PCR assays
are available to detect capsule types, which is important in assessingcapsule-specific disease burden and guiding vaccination decisions.
Given that the majority of invasive disease cases caused by H. influen-
zae are due to serotype b, few assays detecting the remaining five
capsules have been developed, although a PCR-endpoint based assay
can be used to detect H. influenzae serotypes [52,53]. Multiple capsu-
lar polysaccharides are associated with invasive disease and, differen-
tiation of these capsules is essential (Table 2). Assays have been
developed that detect meningococcal or pneumococcal capsules
associated with invasive disease [45,54]. Whilst rtPCR assays to
detect meningococcal serogroups A, B, C, W, Y, and X have been devel-
oped, the complexity of the pneumococcal capsular locus and large
number of serotypes make the design of multiple PCR assays capable
of detecting a large number of potential serotypes a major challenge
[55,56]. Most assays focus on detecting a subset of the prevalent sero-
types circulating in a region and/or those most frequently associated
with invasive disease. An alternative approach determines serotypes
based on the capsule polymerase gene wzh [57].
There are ten GBS serotypes and six serotypes (Ia, Ib, II, III, IV and
V), in particular, are associated with invasive disease. Few rtPCR
assays have been designed to detect the presence of S. agalactiae
with one based on the dltS gene, a sensor protein, and capsule-spe-
cific genes encoding serotypes Ia, Ib, and III [58,59]. The assay is spe-
cies-specific for GBS with no cross-reaction with other closely related
Streptococcus spp and it reliably detects serotypes Ia, Ib, and III.
1.5. Loop-mediated isothermal amplification assays (LAMP)
The loop-mediated isothermal amplification (LAMP) assay was
developed in 2000 [60]. This assay amplifies a specific DNA target
and has the advantage of working in isothermal conditions, removing
the requirement for thermocyclers. LAMP uses a DNA polymerase
that has strand displacement activity, allowing it to separate the dou-
ble-stranded DNA without the need for a temperature change and
thus the reaction can be conducted in a simple water bath. In addition
to requiring very basic equipment, LAMP assays have been found to
be highly specific [61] and their efficiency is less affected by back-
ground DNA [60]. As a result, several LAMP assays have been
designed for the diagnosis of bacterial pathogens, including the four
pathogens included in this review.
A LAMP assay to detect Hib directly from CSF was described in
2011 [62], which targeted a 247 bp nucleotide sequence of the cap-
sule locus and was performed at 65 °C for 35 min. The method was
evaluated using a collection of H. influenzae isolates, other Haemophi-
lus species, and other genera, as well as stored CSF samples originat-
ing from suspected meningitis cases. The Hib LAMP assay
discriminated Hib from other encapsulated H. influenzae strains and
was more sensitive than the bexA PCR assay and a nested PCR for the
detection of Hib [62]. Another study used a similar design to develop
five LAMP assays for the characterisation of non-serotype b H. influ-
enzae isolates [63]. Validation was performed using a collection of H.
influenzae isolates, other Haemophilus species, other genera, and
spiked CSF samples. This non-serotype b LAMP assay was as specific
and sensitive as the comparable non-serotype b PCR assay, and
results were confirmed by dideoxy nucleotide sequencing of the
products [63].
A LAMP assay for the detection of N. meningitidis uses primers that
target the ctrA gene. This assay performed as well as the standard
rtPCR, but at a fraction of the cost and time [64]. The method was
assessed as a point-of-care diagnostic tool at the emergency depart-
ment of the Royal Belfast Hospital for Sick Children, UK [65]: A total
of 161 patients had nasopharyngeal and blood samples tested using
the LAMP assay in addition to the routine culture and PCR but the
assay was not validated for CSF specimens. Similarly, a LAMP assay
targeting the lytA gene of S. pneumoniae was developed and validated
using a set of reference strains that included different Streptococcus
species and other genera, clinical alpha-haemolytic streptococcal
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lytA LAMP assay was found to be more sensitive than the comparable
lytA PCR.
Multiplex LAMP assays have been more difficult to design
because of the non-exonuclease activity of the polymerase enzyme,
which prevents the use of labelled probes; however, the ability to
detect multiple pathogens in a single reaction has been explored in
the context of meningitis. A prototype LAMP assay was designed to
detect S. pneumoniae, Staphylococcus aureus, Streptococcus suis, and
GBS based on the sequence diversity of the 16 rRNA genes of each
bacterial species [67], which exhibited better sensitivity and a lower
limit of detection than conventional PCR. It was specific, although
only three other bacterial species were tested for cross-reactivity
(N. meningitidis, H. influenzae, and Escherichia coli). The assay was
validated with DNA extracted from cultured isolates but was not
tested on CSF.
A modified LAMP assay, the Tth Endonuclease Cleavage (TEC)
LAMP, has been developed, allowing simultaneous detection of N.
meningitidis, S. pneumoniae, and H. influenzae [68]. This assay includes
a thermostable enzyme capable of cleaving abasic sites in double-
stranded DNA, along with a TEC primer/probe, which acts as a LAMP
forward inner primer, but which also contains an abasic site, a fluo-
rescent dye, and a quencher [68]. The addition of the fluorescent dye
allows multiplexing and real-time monitoring of the amplification.
The assay targets the genes encoding: (i) A heparinase II/III-like pro-
tein in S. pneumoniae (SPNA45_01710); (ii) A putative cytolysin secre-
tion ABC transporter protein in N. meningitidis (NMO_1242; hylB);
and (iii) A phosphate transport system permease protein in Hib
(pstA). A random gene fragment is incorporated as an internal control
[68]. This prototype assay was validated using a panel of DNA
extracted from reference and clinical isolates and tested in PCR-con-
firmed cases of S. pneumoniae, N. meningitidis, and H. influenzae infec-
tions. The specificity was 100% for each target and pathogen-specific
sensitivity was 95.7% for S. pneumoniae, 100% for N. meningitidis and
80% for H. influenzae. Although the reactions were conducted in a
rtPCR thermocycler, this assay could also be performed with simpler
point-of-care technologies that allow sample heating and fluorescent
detection [69]. An improvement of the (TEC)-LAMP method is loop-
primer endonuclease cleavage (LEC)-LAMP, which allows single
nucleotide polymorphisms to be detected in either singleplex or mul-
tiplex assays [70]. This assay successfully resulted in the simulta-
neous detection of N. meningitidis, S. pneumoniae, and H. influenzae
and may be useful in the detection of allele-specific differences
between and within bacterial species in a single assay. Finally, a com-
mercial LAMP assay called the eazyplex CSF direct panel is available
and has the capacity to detect several pathogens associated with
meningitis, including E. coli, H. influenzae, L. monocytogenes, N. menin-
gitidis, S. agalactiae, and S. pneumoniae. The average cost of this assay
was estimated to be around $62 (around £45/€50) per sample and
was relatively easy to use with a sensitivity of 90.9% and specificity of
100% [71].
Ultimately, LAMP technology could be developed into affordable
point-of-care devices such as paper-based LAMP assays that allow
the simultaneous detection of S. agalactiae, S. pneumoniae and S.
aureus using dry reagents that are easy to store and transport in
LMICs [72]. Improvements in LAMP methodologies that could allow
for real-time monitoring system without post-amplification manipu-
lations make these assays potential candidates for the molecular
diagnosis of infectious diseases such as meningitis. The pooled high
sensitivity and specificity values determined from a review of LAMP
assays detecting the meningococcus are encouraging [73] and the
design of a multiplex LAMP assay including all four pathogens
included in this review is now a possibility. Such an assay would be
invaluable for use in hospital settings and the lack of requirements
for expensive equipment makes it an appealing approach for labora-
tories with limited resources.1.6. Sensitivities and specificities of published assays
The sensitivity and specificity values of various singleplex rtPCR
assays were high, ranging from 91 to 100% (Table 3). Multiplex assays
targeting S. pneumoniae, N. meningitidis and H. influenzae were
reported to have sensitivities ranging from 73 to 94%, and good spe-
cificities (98 to 100%), comparable to those of singleplex rtPCR assays.
LAMP assays were found to generate both higher sensitivity and
specificity values compared to rtPCR (Table 3). The accuracy of LAMP
assays was consistently high (sensitivity of 80100% and specificity
of 99100%) using various clinical samples including CSF, blood and
nasopharyngeal swabs from children.
Among PCR-based tests, the sensitivity and specificity values were
higher for CSF samples than for either blood samples or oro-nasopha-
ryngeal swabs for the diagnosis of meningitis; however, using LAMP
assays that target ctrA loci for the diagnosis of invasive meningococ-
cal disease, the sensitivity and specificity values were similar regard-
less of the sample used [65]. Nonetheless, further studies are needed
to clearly elucidate whether other non-CSF specimens are suitable
for LAMP diagnosis of meningococcal disease.
2. Outstanding questions
In the longer term, whole genome sequencing (WGS) will become
more routinely employed in the diagnosis of infectious diseases,
including meningitis [74]. Ultimately, this will likely include the
development of non-culture-based methods that directly sequence
pathogen genomes from clinical specimens. Current requirements for
these approaches include DNA extraction protocols that deplete
human DNA and increase the bacterial sequence yield [75]. Such
assays will have the benefit of allowing multiple genetic targets to be
analysed directly from genomes, enabling the simultaneous identifi-
cation of the pathogen, the predicted capsular type, antimicrobial
resistance determinants, etc. Progress has been made in this respect
with selective whole-genome amplification (SWGA), an isothermal
multiple-displacement amplification-based method, validated in 12
CSF specimens from invasive meningococcal disease cases [76]. In
addition, metagenomic next generation sequencing is also showing
promise in improving the diagnosis of meningitis and encephalitis
[77,78]. Oxford Nanopore sequencing technology was recently
employed in Zambia for the rapid diagnosis of bacterial meningitis
species through the sequencing of 16S rRNA [79].
To reach the goal of implementing WGS in LMICs, a range of tech-
nical, financial, and infrastructural challenges will have to be met
and, until then, it is unlikely laboratories in LMICs will be able to rou-
tinely undertake WGS for the diagnosis of meningitis. In the immedi-
ate future, the most promising opportunities involve refining
molecular diagnostic assays using comparative genomic analyses to:
(i) Improve practices of sampling, storage and transport of speci-
mens; (ii) Improve the performance of existing targets by increasing
sensitivity and specificity; and (iii) Identify alternative diagnostic tar-
gets to enhance species-specificity [80]. In order to undertake such
activities, an enhanced representation of genomes originating from
LMICs needs to be established and initiatives such as the Global Men-
ingitis Partnership seek to address this issue [81]. Furthermore, the
analysis and comparison of genomes relies on the availability of data-
bases where genomes can be stored, curated and analysed. For exam-
ple, PubMLST databases (https://pubmlst.org) store and annotate
thousands of genomes (with associated metadata) of all four bacterial
species included in this review in dedicated genome libraries [82]
and BMGAP allows users to deposit and access N. meningitidis and H.
influenzae genomes using a secure online portal [83].
The timely diagnosis of the aetiological agent in meningeal infec-
tions is essential to facilitate treatment, patient management, and
improved clinical outcomes. The most desirable diagnostic assay
would be one in which multiple pathogens can be detected in a cost-
8 K. Diallo et al. / EBioMedicine 65 (2021) 103274effective, easy to use system that provides rapid and robust results.
This review has found that extensive progress has been made in the
development of diagnostic methods for meningitis; however, it is
likely that multiple approaches will still be required, and cost and
ease of use are major influencing factors in the choice and utility of
diagnostic tests.
2.1. Search strategy and selection criteria
Three independent reviewers searched for relevant publications
dating from 2010 to 2020 using the Medical Subject Headings
(MeSH): ‘molecular diagnostics’ AND ‘bacterial meningitis’; or
‘molecular diagnostics’ AND ‘Haemophilus influenzae’ or ‘Neisseria
meningitidis’ or ‘Streptococcus pneumoniae’ or ‘Streptococcus agalac-
tiae’. The terms ‘Hib’ and ‘group B streptococcus’ were also included.
The electronic literature databases Medline/Ovid, PubMed, Web of
Science, Embase and Global Health were used. Assays designed to
identify bacterial polysaccharide capsules were also selected. Publica-
tions describing viral, Mycobacterium tuberculosis, respiratory or ani-
mal infections, were excluded as were articles that: (i) Did not
include full texts; (ii) Were duplicated; (iii) Described MALDI-ToF
assays; or (iv) were not in English.
Sensitivity and specificity values were derived by determining
True Positive (TP), False Positive (FP), False Negative (FN) and True
Negative (TN) values from appropriate published assays. The refer-
ence ‘standard’ was determined to be a culture-based result and a
molecular assay was the ‘test’ result.
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